Ibu-Lysin Dexcel (Ibuprofen D,l-Lysinate)

Ibuprofen lysinate works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for prostaglandin synthesis. By lowering prostaglandin levels, it reduces inflammation, alleviates pain, and helps lower elevated body temperature.

The appropriate dose of Ibu-Lysin Dexcel is determined by the prescribing clinician based on the patient’s age, weight, medical condition, and response to therapy. Standard adult dosing ranges are outlined in clinical guidelines, but the exact regimen should always be set by a qualified prescriber.

Safety of ibuprofen lysinate in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Ibuprofen lysinate is a lysine salt form of ibuprofen that offers improved aqueous solubility, which can lead to faster absorption and onset of action compared with standard ibuprofen tablets. Efficacy and safety profiles are generally comparable, though individual response may vary.

Store Ibu-Lysin Dexcel at room temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in extreme heat or humidity, and keep out of reach of children.

Ibu-Lysin Dexcel is taken orally with a glass of water. It may be taken with or without food, although taking it with food can help reduce gastrointestinal discomfort in some patients.

Serious risks include gastrointestinal bleeding or ulceration, severe allergic reactions such as anaphylaxis, renal impairment, hepatic dysfunction, and cardiovascular events like heart attack or stroke. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Individuals with known hypersensitivity to ibuprofen, other NSAIDs, or any component of the formulation should avoid it. It is also contraindicated in patients with active gastrointestinal ulcer disease, severe renal or hepatic impairment, and those at high risk for cardiovascular events unless specifically advised by a physician.